Primary lung cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)Clinically suspected or diagnosed primary lung cancer. 2)FEV1.0/FVC < 0.70, assessed by spirometry. 3)Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria I-III. 4)Modified Medical Research Council (MRC) score =<1. 5)Resectable cancer lesion by single lobectomy. 6)No previous treatment of COPD or asthma. 7)No past history of pulmonary resection. 8)Patients being able to stop smoking at the time of the registry to this trial. 9)Adequate organ function tolerable for the general anesthesia. 10)Capable for inhalation. 11)Age of 20 years or older. 12)ECOG performance status: 0, 1 13)Written informed consent to participate.
Exclusion criteria
Exclusion criteria: 1)Median sternotomy. 2)Combined resection of the chest wall. 3)Active infection. 4)Active double cancer. 5)Current or previous history of severe heart diseases or cerebrovascular disases. Uncontrolled diabetes mellitus or hypertension. Interstitial pneumonia. Arrhythmia requiring antiarrhythmic continuously. Renal dysfunction necessitating blood purification therapy. 6)Patients with psychiatric disease. 7)Patients requiring systemic steroids medication. 8)Pregnant and lactating female, female who has possibility of pregnancy. 9)Past history of drug allergy. 10)Hypokalemia. 11)Patients who were judged inappropriate to enter this trial by physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of pulmonary function associated with inhalation of Salmeterol | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Rate of postoperative complications 2) Self-assessment of respiratory insufficiency 3) 1-year overall survival 4) Rate of adverse events 5) Evaluation of postoperative compliance | — |
Countries
Japan
Contacts
Yamanashi Prefectural Central Hospital General Thoracic Surgery